Subscribe To

Price Alert Latest News Economic Calendar News

GMDA / Gamida Cell shares jump on FDA recognition of allogeneic cell therapy

Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidate Omisirge received breakthrough therapy designation, priority review and orphan drug designation from the FDA, sending shares of the Boston-based company nearly 45% higher in midday trading. Read More

Demo Live Account See Partner Details

Content Topics

Gamida

Cell

Jump

Recognition

Allogeneic

Therapy

Stock

GMDA

Posted: Apr 18 2023, 12:13

Author Name: Proactive Investors

GMDA News

By Seeking Alpha
August 14, 2023

Gamida Cell: The Treacherous Path To Profitability

Gamida Cell's approved therapy, Omisirge, shows faster neutrophil recovery and reduced infections in blood cancer patients compared to standard care.

By Zacks Investment Research
June 9, 2023

Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden Cross

Gamida Cell Ltd. (GMDA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.

By Seeking Alpha
May 15, 2023

Gamida Cell Ltd. (GMDA) Q1 2023 Earnings Call Transcript

Gamida Cell Ltd. (NASDAQ:GMDA ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Mike Kuczkowski - Corporate Communication

By Business Wire
May 11, 2023

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced tha

By PennyStocks
May 10, 2023

Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today

Penny stocks with unusual options activity today The post Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today appeared first on Penny Stocks

By InvestorPlace
April 19, 2023

Why Is Gamida Cell (GMDA) Stock Down 19% Today?

Gamida Cell (NASDAQ: GMDA ) stock is falling on Wednesday after the cell therapy company revealed details of a public securities offering. According t

By MarketBeat
April 18, 2023

Gamida Cell Stock Jumps Over 100% on FDA Approval

Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fi

By Proactive Investors
April 18, 2023

Gamida Cell shares jump on FDA recognition of allogeneic cell therapy

Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidat

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.